 Veru Inc NASDAQ: VERU has announced positive efficacy and safety results from a planned interim analysis of Phase 3 COVID-19 trial evaluating oral sabizabulin 9 mg versus placebo. The trial included 150 hospitalized COVID-19 patients at high risk for Acute Respiratory Distress. 